Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Visual Acuity | 14 | 2024 | 113 | 2.000 |
Why?
|
| Macular Degeneration | 6 | 2023 | 176 | 1.980 |
Why?
|
| Tomography, Optical Coherence | 18 | 2024 | 201 | 1.900 |
Why?
|
| Retinal Diseases | 4 | 2024 | 30 | 1.610 |
Why?
|
| Angiogenesis Inhibitors | 7 | 2024 | 78 | 1.540 |
Why?
|
| Macular Edema | 3 | 2024 | 24 | 1.510 |
Why?
|
| Wet Macular Degeneration | 3 | 2022 | 23 | 1.350 |
Why?
|
| Retinal Vasculitis | 2 | 2022 | 7 | 0.990 |
Why?
|
| Ranibizumab | 3 | 2022 | 20 | 0.950 |
Why?
|
| Intravitreal Injections | 8 | 2024 | 49 | 0.950 |
Why?
|
| Retinal Vein Occlusion | 1 | 2024 | 18 | 0.890 |
Why?
|
| Geographic Atrophy | 4 | 2024 | 20 | 0.870 |
Why?
|
| Hawks | 1 | 2022 | 1 | 0.810 |
Why?
|
| Fluorescein Angiography | 8 | 2023 | 52 | 0.800 |
Why?
|
| Retinal Dystrophies | 1 | 2021 | 4 | 0.780 |
Why?
|
| Peripherins | 1 | 2021 | 14 | 0.780 |
Why?
|
| Retina | 3 | 2024 | 119 | 0.750 |
Why?
|
| Cysts | 2 | 2013 | 37 | 0.710 |
Why?
|
| Endotamponade | 1 | 2020 | 6 | 0.690 |
Why?
|
| Retinal Perforations | 1 | 2020 | 7 | 0.680 |
Why?
|
| Basement Membrane | 1 | 2020 | 25 | 0.680 |
Why?
|
| Diabetic Retinopathy | 2 | 2021 | 45 | 0.680 |
Why?
|
| Fovea Centralis | 2 | 2023 | 17 | 0.670 |
Why?
|
| Vitrectomy | 1 | 2020 | 20 | 0.670 |
Why?
|
| Vitreous Body | 3 | 2024 | 31 | 0.630 |
Why?
|
| Choroid Neoplasms | 2 | 2016 | 21 | 0.610 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2016 | 201 | 0.580 |
Why?
|
| Laser Coagulation | 3 | 2016 | 14 | 0.580 |
Why?
|
| Ectopia Lentis | 1 | 2014 | 1 | 0.480 |
Why?
|
| Marfan Syndrome | 1 | 2014 | 17 | 0.470 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2014 | 7 | 0.470 |
Why?
|
| Nocardia | 1 | 2014 | 1 | 0.460 |
Why?
|
| Nocardia Infections | 1 | 2014 | 2 | 0.460 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 45 | 0.460 |
Why?
|
| Eye Infections, Bacterial | 1 | 2014 | 5 | 0.460 |
Why?
|
| Endophthalmitis | 1 | 2014 | 11 | 0.460 |
Why?
|
| Retinal Drusen | 1 | 2014 | 16 | 0.460 |
Why?
|
| Eye Injuries | 1 | 2014 | 14 | 0.450 |
Why?
|
| Humans | 32 | 2024 | 59495 | 0.450 |
Why?
|
| Lasers | 1 | 2014 | 33 | 0.450 |
Why?
|
| Blindness | 1 | 2014 | 37 | 0.450 |
Why?
|
| Radiosurgery | 1 | 2014 | 61 | 0.450 |
Why?
|
| Muscle Cramp | 1 | 2013 | 2 | 0.430 |
Why?
|
| POEMS Syndrome | 1 | 2013 | 2 | 0.430 |
Why?
|
| Femoral Neoplasms | 1 | 2013 | 5 | 0.430 |
Why?
|
| Conjunctival Diseases | 1 | 2013 | 2 | 0.430 |
Why?
|
| Strabismus | 1 | 2013 | 2 | 0.430 |
Why?
|
| Pigment Epithelium of Eye | 2 | 2015 | 12 | 0.420 |
Why?
|
| Bevacizumab | 3 | 2024 | 57 | 0.350 |
Why?
|
| Retinal Pigment Epithelium | 3 | 2015 | 26 | 0.350 |
Why?
|
| Choroidal Neovascularization | 2 | 2023 | 29 | 0.340 |
Why?
|
| Adult | 11 | 2024 | 15783 | 0.320 |
Why?
|
| Male | 16 | 2024 | 27562 | 0.310 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2022 | 33 | 0.300 |
Why?
|
| Multiple Myeloma | 1 | 2013 | 322 | 0.300 |
Why?
|
| Eye Diseases | 1 | 2008 | 37 | 0.290 |
Why?
|
| Postoperative Complications | 1 | 2013 | 1134 | 0.270 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2022 | 502 | 0.260 |
Why?
|
| Female | 16 | 2024 | 30908 | 0.260 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 1129 | 0.260 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 2329 | 0.250 |
Why?
|
| Aged | 8 | 2024 | 13339 | 0.240 |
Why?
|
| Subretinal Fluid | 2 | 2022 | 3 | 0.240 |
Why?
|
| Amyl Nitrite | 1 | 2024 | 3 | 0.230 |
Why?
|
| Treatment Outcome | 4 | 2024 | 5183 | 0.220 |
Why?
|
| Middle Aged | 8 | 2024 | 16275 | 0.200 |
Why?
|
| Choroid Diseases | 1 | 2021 | 4 | 0.200 |
Why?
|
| Pedigree | 1 | 2021 | 190 | 0.190 |
Why?
|
| Uveitis | 1 | 2021 | 30 | 0.180 |
Why?
|
| Prone Position | 1 | 2020 | 27 | 0.170 |
Why?
|
| Postoperative Period | 1 | 2020 | 125 | 0.170 |
Why?
|
| Double-Blind Method | 3 | 2024 | 680 | 0.150 |
Why?
|
| Fundus Oculi | 1 | 2016 | 17 | 0.130 |
Why?
|
| Osteoma | 1 | 2016 | 1 | 0.130 |
Why?
|
| Posterior Eye Segment | 1 | 2016 | 1 | 0.130 |
Why?
|
| Eye Infections, Viral | 1 | 2016 | 4 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 1463 | 0.130 |
Why?
|
| Coxsackievirus Infections | 1 | 2016 | 12 | 0.130 |
Why?
|
| Retrospective Studies | 4 | 2024 | 6008 | 0.130 |
Why?
|
| Retinal Detachment | 1 | 2016 | 17 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 220 | 0.130 |
Why?
|
| Varicose Veins | 1 | 2015 | 7 | 0.120 |
Why?
|
| Albinism, Oculocutaneous | 1 | 2015 | 1 | 0.120 |
Why?
|
| Iris Diseases | 1 | 2015 | 2 | 0.120 |
Why?
|
| Lenses, Intraocular | 1 | 2015 | 4 | 0.120 |
Why?
|
| Venous Pressure | 1 | 2015 | 2 | 0.120 |
Why?
|
| Retinal Neoplasms | 1 | 2015 | 16 | 0.120 |
Why?
|
| Valsalva Maneuver | 1 | 2015 | 12 | 0.120 |
Why?
|
| Retinal Hemorrhage | 1 | 2015 | 8 | 0.120 |
Why?
|
| Choroid | 1 | 2015 | 25 | 0.120 |
Why?
|
| Macula Lutea | 1 | 2015 | 21 | 0.120 |
Why?
|
| Central Serous Chorioretinopathy | 1 | 2014 | 2 | 0.120 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2014 | 7 | 0.120 |
Why?
|
| Lens, Crystalline | 1 | 2014 | 15 | 0.120 |
Why?
|
| Tuberous Sclerosis | 1 | 2014 | 11 | 0.120 |
Why?
|
| Global Health | 1 | 2016 | 163 | 0.120 |
Why?
|
| Hypopigmentation | 1 | 2015 | 17 | 0.120 |
Why?
|
| Aged, 80 and over | 4 | 2023 | 5089 | 0.120 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 79 | 0.120 |
Why?
|
| Remission Induction | 1 | 2014 | 137 | 0.120 |
Why?
|
| Mycophenolic Acid | 1 | 2014 | 32 | 0.120 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2014 | 9 | 0.120 |
Why?
|
| Indoles | 1 | 2014 | 98 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 900 | 0.110 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 127 | 0.110 |
Why?
|
| Mutation | 1 | 2021 | 2429 | 0.110 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 2013 | 5 | 0.110 |
Why?
|
| Exercise Test | 1 | 2015 | 234 | 0.110 |
Why?
|
| Phlebography | 1 | 2013 | 44 | 0.110 |
Why?
|
| Papilledema | 1 | 2013 | 10 | 0.110 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 454 | 0.110 |
Why?
|
| Child | 3 | 2014 | 4304 | 0.110 |
Why?
|
| Incidence | 1 | 2016 | 1237 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2014 | 139 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 323 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 848 | 0.100 |
Why?
|
| Vision Disorders | 3 | 2016 | 59 | 0.090 |
Why?
|
| Uveal Neoplasms | 1 | 2009 | 52 | 0.080 |
Why?
|
| Supine Position | 1 | 2008 | 31 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2014 | 1914 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 276 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 2468 | 0.070 |
Why?
|
| Melanoma | 1 | 2009 | 334 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 3101 | 0.060 |
Why?
|
| Indocyanine Green | 2 | 2015 | 11 | 0.060 |
Why?
|
| Coloring Agents | 2 | 2015 | 54 | 0.060 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2024 | 43 | 0.060 |
Why?
|
| Animals | 1 | 2022 | 19648 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 2040 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 809 | 0.050 |
Why?
|
| Patient Selection | 1 | 2024 | 446 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 442 | 0.050 |
Why?
|
| Adolescent | 3 | 2016 | 5930 | 0.040 |
Why?
|
| Time Factors | 1 | 2024 | 3579 | 0.030 |
Why?
|
| Retinitis | 1 | 2016 | 6 | 0.030 |
Why?
|
| Miosis | 1 | 2015 | 2 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 67 | 0.030 |
Why?
|
| Melanins | 1 | 2015 | 19 | 0.030 |
Why?
|
| Prednisolone | 1 | 2014 | 8 | 0.030 |
Why?
|
| Ketorolac | 1 | 2014 | 11 | 0.030 |
Why?
|
| Nonprescription Drugs | 1 | 2014 | 18 | 0.030 |
Why?
|
| Acne Vulgaris | 1 | 2014 | 24 | 0.030 |
Why?
|
| Headache | 1 | 2014 | 63 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1102 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 436 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2014 | 171 | 0.030 |
Why?
|
| Young Adult | 2 | 2016 | 4329 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 202 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 1157 | 0.020 |
Why?
|
| Eye Enucleation | 1 | 2009 | 11 | 0.020 |
Why?
|
| Cryotherapy | 1 | 2009 | 12 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 2009 | 19 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2009 | 40 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2009 | 1839 | 0.010 |
Why?
|
| Risk Factors | 1 | 2009 | 5015 | 0.010 |
Why?
|